background
current
drug
proven
effect
treat
cat
felin
infecti
periton
fip
hypothesi
propentofyllin
ppf
decreas
vascul
therefor
prolong
surviv
time
cat
fip
increas
qualiti
life
anim
twentythre
privat
own
cat
fip
method
placebocontrol
doubleblind
trial
fip
confirm
histolog
immunostain
felin
coronaviru
fcov
antigen
effus
tissu
macrophag
cat
randomli
select
treatment
either
ppf
placebo
cat
receiv
addit
treatment
glucocorticoid
antibiot
low
molecular
weight
heparin
accord
method
result
statist
signific
differ
surviv
time
cat
treat
ppf
day
ci
versu
placebo
day
ci
median
surviv
time
cat
day
day
neither
differ
qualiti
life
day
p
amount
effus
day
p
tumor
necrosi
factoralpha
tnfa
concentr
day
p
variabl
investig
studi
includ
complet
blood
count
small
anim
biochemistri
profil
conclus
clinic
import
studi
detect
effect
ppf
surviv
time
qualiti
life
clinic
laboratori
paramet
cat
fip
therefor
ppf
appear
effect
treatment
option
cat
late
stage
diseas
fip
f
elin
infecti
periton
fip
one
frequent
caus
death
young
cat
proven
record
cat
confirm
diagnosi
recov
fip
thu
fip
usual
lethal
control
studi
verifi
success
treatment
use
date
therefor
provid
object
evid
effect
treatment
diseas
import
sever
case
report
found
onlin
veterinari
inform
network
http
wwwvincom
describ
posit
effect
methylxanthin
deriv
pentoxifyllin
ptx
trental
surviv
time
cat
fip
sever
veterinarian
wellknown
specialist
felin
medicin
suggest
use
ptx
effect
treat
cat
fip
accord
report
ptx
cure
suggest
prolong
life
cat
report
suggest
ptx
like
decreas
vascul
respons
major
clinicopatholog
find
fip
mode
action
methlyxanthin
deriv
fulli
understood
mechan
remain
unknown
ptx
inhibit
sever
cytokin
interleukin
tumor
necrosi
factoralpha
tnfa
studi
rat
human
vivo
vitro
describ
inhibit
cytokin
ptx
ptx
methylxanthin
deriv
seem
suppress
tnfa
synthesi
proinflammatori
cytokin
play
major
role
pathogenesi
vascul
therefor
suggest
vascul
may
effect
control
ptx
effect
neutral
suppress
cytokin
propentofyllin
ppf
ptx
mainli
trial
use
peopl
peripher
vascular
diseas
cerebrovascular
diseas
alzheim
diseas
brain
ischemia
cerebrovascular
insuffici
endotoxemia
ischem
heart
diseas
tnfa
also
induc
fibrinogen
synthesi
respons
increas
product
free
radic
alt
alanin
aminotransferas
ap
alkalin
phosphatas
ci
confid
interv
fcov
felin
coronaviru
felv
felin
leukemia
viru
fip
felin
infecti
periton
fipv
felin
infecti
periton
viru
fiv
felin
immundefici
viru
ifat
immunofluoresc
antibodi
techniqu
ppf
propentofyllin
ptx
pentoxifyllin
rbc
red
blood
cell
spss
statist
packag
social
scienc
tnfa
tumor
necrosi
factoralpha
tp
total
protein
wbc
white
blood
cell
caus
endotheli
cell
damag
inhibit
synthesi
tnfa
activ
monocyt
ptx
probabl
decreas
fibrinogen
level
common
compon
effus
cat
fip
previous
postul
high
fibrinogen
level
could
index
tnfa
level
find
support
close
correl
decreas
fibrinogen
level
clinic
improv
studi
geriatr
cachexia
human
addit
show
ptx
may
decreas
cachexia
downregul
proinflammatori
cytokin
tnfa
interleukin
serotonin
interferonc
cat
fip
often
anorect
consid
anoth
posit
effect
methylxanthin
deriv
wellb
cat
fip
ppf
anoth
methylxanthin
deriv
licens
sever
european
countri
includ
germani
veterinari
use
dog
similar
ptx
licens
germani
veterinari
use
chemic
structur
well
pharmacolog
effect
ptx
ppf
inhibit
sever
cytokin
interleukin
tnfa
furthermor
ppf
alreadi
appli
secur
effect
cat
felin
asthma
therefor
ppf
instead
ptx
use
studi
aim
studi
evalu
efficaci
ppf
surviv
time
qualiti
life
cat
confirm
diagnosi
fip
placebocontrol
doubleblind
trial
studi
includ
clientown
cat
inclus
criterion
enter
studi
definit
diagnosi
fip
cat
present
clinic
small
anim
intern
medicin
lmu
univers
munich
germani
inform
consent
particip
sign
owner
obtain
cat
studi
fulfil
gener
german
guidelin
prospect
studi
owner
consent
approv
ethic
committe
anim
protect
offici
regierung
von
oberbayern
germani
permiss
consecut
case
cat
confirm
fip
owner
will
particip
studi
present
clinic
april
decemb
enter
studi
diagnosi
fip
either
confirm
detect
felin
coronaviru
fcov
antigen
macrophag
effus
use
direct
immunofluoresc
n
histopatholog
examin
tissu
posit
immunohistochem
stain
fcov
antigen
macrophag
n
cat
felin
immundefici
viru
fiv
progress
felin
leukemia
viru
felv
infect
includ
studi
snap
felv
fiv
test
b
cat
sever
clinic
sign
karnofski
score
surviv
time
less
hour
treatment
initi
retrospect
exclud
cat
one
cat
exclud
retrospect
lack
owner
complianc
seventeen
cat
european
shorthair
cat
british
shorthair
cat
one
follow
breed
birman
persian
norwegian
forest
cat
persian
crossbr
youngest
cat
week
old
oldest
cat
year
mean
year
median
year
interquartil
rang
year
fifteen
cat
younger
month
cat
younger
year
seventeen
cat
male
neuter
femal
neuter
studi
design
placebocontrol
doubleblind
random
trial
cat
randomli
assign
ppf
n
placebo
group
n
dosag
ppf
base
dosag
use
ptx
treat
cat
fip
literatur
anecdot
case
report
differ
author
report
mgkg
mgcat
everi
hour
given
po
accord
studi
human
ppf
ptx
use
dosag
cat
studi
therefor
receiv
median
dosag
mgkg
ppf
c
whole
studi
period
altern
cat
receiv
similar
amount
tablet
placebo
e
contain
lactos
magnesium
stearat
cellulos
everi
hour
po
ppf
placebo
pill
code
therefor
veterinarian
owner
give
pill
blind
ident
treatment
code
broken
cat
treat
result
includ
surviv
time
karnofski
score
blood
effus
variabl
volum
collect
effus
obtain
blind
cat
also
treat
glucocorticoid
case
effus
day
present
n
dexamethason
f
mgkg
given
intraperiton
intrathorac
depend
locat
effus
everi
hour
day
thoracoor
abdominocenthesi
cat
without
effus
n
receiv
dexamethason
f
mgkg
sc
day
period
cat
treat
oral
prednisolon
g
h
mgkg
everi
hour
death
addit
cat
receiv
amoxicillinclavulan
acid
mgkg
iv
everi
hour
day
dalteparin
sodium
j
iukg
sc
everi
hour
day
gradual
taper
within
next
day
day
iukg
day
iu
kg
well
fluid
nutrit
treatment
necessari
hospit
cat
properli
vaccin
treat
sc
one
dose
ml
immunglobulin
k
product
contain
antibodi
felin
panleukopeniaviru
felin
herpesviru
felin
caliciviru
product
given
decreas
risk
acquir
infecti
diseas
immun
suppress
glucocorticoid
treatment
hospit
glucocorticoid
given
current
treatment
thought
benefici
effect
cat
fip
although
control
studi
antibiot
administ
minim
risk
bacteri
infect
paracentesi
perform
daili
effus
present
high
dosag
glucocorticoid
treatment
cat
also
receiv
low
molecular
weight
heparin
dalteparid
sodium
minim
risk
dissemin
intravascular
coagul
dic
often
observ
cat
fip
cat
either
hospit
day
treatment
initi
present
clinic
daili
physic
ultrasound
examin
perform
daili
gener
condit
character
karnofski
score
index
enabl
judgment
qualiti
life
wellb
cat
mean
score
dead
absolut
healthi
happi
day
day
inclus
studi
well
control
day
day
complet
physic
examin
perform
blood
collect
cbc
perform
automat
analyz
celldyn
l
small
anim
biochemistri
profil
see
tabl
examin
use
automat
analyz
hitachi
aliquot
serum
sampl
preserv
detect
tnfa
present
effus
aspir
amount
record
depend
health
statu
cat
return
owner
day
owner
ask
fill
provid
diari
record
temperatur
respiratori
rate
weight
gener
condit
durat
sleep
time
eat
play
groom
behavior
everi
day
well
problem
notic
owner
followup
examin
clinic
schedul
day
includ
physic
examin
examin
cbc
small
anim
biochemistri
profil
ultrasound
detect
presenc
effus
tnfa
measur
serum
day
use
elisa
n
elisa
valid
cell
cultur
supernat
spike
experi
use
serum
sampl
perform
serum
compon
impact
accuraci
elisa
result
may
interfer
antibodi
bind
show
crossreact
assess
recoveri
serum
sampl
assess
accuraci
measur
valu
pg
tnfa
spike
serum
sampl
healthi
cat
sampl
dilut
sampl
diluent
pb
fetal
calf
serum
p
yield
sampl
contain
pg
control
sampl
diluent
spike
dilut
accordingli
spike
undilut
control
yield
result
expect
rang
spike
undilut
serum
sampl
show
recoveri
indic
inhibitor
detect
serum
serum
dilut
show
recoveri
compar
dilut
control
recoveri
loss
consid
accept
interfer
inhibit
compon
appear
sever
serum
sampl
therefor
dilut
detect
tnfa
elisa
perform
accord
manufactur
instruct
micropl
n
coat
captur
antibodi
overnight
incub
next
day
well
wash
sampl
dilut
standard
n
incub
hour
room
temperatur
wash
detect
antibodi
n
ad
incub
anoth
hour
room
temperatur
detect
streptavidinhrp
n
use
tetramethylbenzidin
n
substrat
solut
reaction
stop
minut
sulfur
acid
n
elisa
measur
bio
tek
reader
q
data
analysi
perform
use
data
analysi
softwar
r
cat
randomli
assign
group
ppf
group
placebo
group
power
analysi
perform
start
studi
use
pass
http
wwwncss
compass
analysi
clinic
relev
differ
median
surviv
time
set
day
assum
anim
treat
ppf
would
surviv
least
day
longer
anim
receiv
placebo
differ
could
detect
anim
per
group
use
power
signific
level
howev
interim
analysi
surviv
time
perform
cat
treat
cat
studi
time
point
surviv
less
day
median
surviv
time
significantli
differ
group
median
surviv
time
ppf
day
placebo
day
therefor
decid
termin
studi
prematur
reason
anim
welfar
expect
clinic
relev
differ
differ
surviv
time
clearli
achiev
statist
analysi
perform
use
statist
softwar
spss
version
http
wwwspsscom
variabl
compar
group
ppf
placebo
group
includ
surviv
time
karnofski
score
red
blood
cell
rbc
hemoglobin
hematocrit
platelet
white
blood
cell
wbc
monocyt
lymphocyt
band
neutrophil
matur
neutrophil
alanin
aminotransferas
alt
alkalin
phosphatas
ap
bilirubin
total
protein
tp
albumin
albumin
globulin
ratio
urea
creatinin
glucos
volum
effus
differ
surviv
time
group
evalu
use
logrank
test
differ
paramet
group
day
day
day
investig
use
mann
whitney
u
test
pvalu
consid
signific
bonferroni
correct
perform
rule
multipl
test
interfer
signific
level
assum
variabl
thu
pvalu
divid
number
test
perform
n
therefor
final
valu
p
variabl
consid
signific
statist
signific
differ
blood
paramet
amount
effus
time
point
cat
treat
ppf
receiv
placebo
tabl
karnofski
score
group
also
show
statist
signific
differ
start
studi
cat
surviv
day
median
day
median
surviv
time
cat
ppf
group
day
rang
confid
interv
ci
cat
placebo
group
median
surviv
time
day
rang
ci
differ
surviv
time
group
significantli
differ
p
fig
twentytwo
cat
surviv
less
day
day
preset
expect
minimum
surviv
time
cat
receiv
ppf
previou
studi
median
surviv
time
day
detect
cat
fip
present
studi
assum
cat
treat
ppf
would
live
least
day
longer
receiv
placebo
median
surviv
day
make
relev
differ
owner
statist
signific
differ
blood
paramet
effus
appar
day
period
treatment
ppf
group
placebo
group
karnofski
score
group
evalu
control
day
day
day
also
show
signific
differ
day
cat
remain
studi
two
improv
karnofski
score
cat
show
differ
karnofski
score
cat
deterior
least
day
cat
remain
studi
karnofski
score
cat
deterior
least
compar
day
statist
evalu
perform
day
cat
aliv
day
next
control
day
cat
ppf
group
placebo
group
serum
sampl
one
time
point
avail
comparison
tnfa
concentr
treatment
ppf
signific
decreas
found
cat
convers
cat
even
show
increas
tnfa
serum
level
studi
period
studi
statist
signific
differ
surviv
time
cat
treat
ppf
versu
placebo
also
statist
signific
differ
variabl
evalu
group
includ
cbc
small
anim
biochemistri
profil
shown
tabl
median
surviv
time
day
cat
fip
definit
diagnosi
studi
nearli
ident
median
surviv
studi
ritz
et
al
report
median
surviv
time
cat
fip
confirm
howev
studi
ritz
et
al
sever
cat
surviv
longer
week
case
present
studi
unfortun
desir
effect
ppf
observ
propos
ppf
may
decreas
volum
effus
inhibit
cytokin
particularli
tnfa
therebi
reduc
result
vascul
neither
signific
differ
amount
effus
ppf
placebo
group
decreas
tnfa
cat
serial
measur
perform
cure
never
ultim
goal
use
ppf
cat
fip
antivir
drug
howev
pharmacolog
featur
assum
posit
effect
wellb
cat
surviv
time
ppf
meant
inhibit
tnfa
product
involv
develop
vascul
tnfa
concentr
howev
decreas
cat
treat
ppf
increas
instead
like
ppf
even
abl
exhibit
function
within
short
period
time
tnfa
increas
mainli
reflect
sever
progress
diseas
reason
lack
effici
multifacet
probabl
reason
treatment
may
initi
late
sign
vascul
appar
immunemedi
process
cat
fip
might
progress
far
delay
ppf
present
studi
cat
alreadi
show
effus
day
present
shown
experiment
trial
sign
fip
becom
appar
week
inocul
mutat
felin
infecti
periton
viru
fipv
effect
ptx
describ
manufactur
inform
seen
week
treatment
initi
assumpt
time
frame
would
appli
ppf
cat
alreadi
dead
effect
could
reach
reason
lack
ppf
effici
studi
could
treatment
interv
could
long
applic
ppf
everi
hour
use
trial
follow
anecdot
report
describ
effect
ptx
cat
manufactur
instruct
recommend
administr
ptx
time
daili
human
medicin
rel
short
plasma
halflif
hour
drug
pharmacokinet
studi
dog
indic
ptx
administ
everi
hour
reason
behind
report
benefici
effect
ptx
describ
case
report
http
wwwvincom
current
unknown
treatment
might
initi
earlier
cat
altern
fip
confirm
histopatholog
immunofluoresc
antibodi
techniqu
ifat
case
cat
could
suffer
diseas
cat
might
noneffus
form
fip
consid
longer
surviv
time
cat
effus
drug
interact
ppf
medic
especi
glucocorticoid
studi
possibl
report
addit
recent
studi
cat
asthma
glucocorticoid
ppf
safe
use
combin
advers
interact
glucocorticoid
dose
reduc
addit
ppf
treatment
therefor
advers
effect
expect
combin
ppf
glucocorticoid
present
studi
glucocorticoid
routin
use
cat
fip
viru
caus
major
damag
cat
immun
reaction
lead
fatal
consequ
evid
base
studi
glucocorticoid
posit
effect
cat
fip
cat
present
studi
receiv
immunosuppress
dose
glucocorticoid
mgkg
togeth
stress
caus
hospit
daili
paracenthesi
glucocorticoid
might
confound
factor
potenti
lower
dose
glucocorticoid
glucocorticoid
might
better
longterm
treatment
benefici
effect
glucocorticoid
treatment
fip
must
question
given
median
surviv
time
day
present
previou
studi
treatment
placebo
group
therefor
futur
treatment
studi
protocol
includ
group
cat
receiv
glucocorticoid
altern
doubleblind
studi
evalu
glucocorticoid
treatment
option
fip
could
perform
statist
signific
differ
karnofski
score
treatment
period
two
group
cat
show
increas
wellb
shortli
particip
studi
like
induc
corticosteroid
effect
ppf
phenomenon
could
observ
group
howev
improv
gener
condit
longlast
cat
deterior
rapidli
day
treatment
initi
studi
sever
limit
limit
unequ
distribut
cat
ppf
placebo
group
blind
random
trial
distribut
could
influenc
anoth
limit
might
small
number
cat
without
initi
effus
definit
diagnosi
cat
without
effus
howev
much
difficult
obtain
ppf
might
use
cat
without
effus
may
chanc
prevent
vascul
therefor
effus
